Landos Biopharma, Inc. (LABP)
- Previous Close
22.35 - Open
22.55 - Bid --
- Ask --
- Day's Range
22.41 - 22.55 - 52 Week Range
2.50 - 22.84 - Volume
7,158 - Avg. Volume
26,120 - Market Cap (intraday)
70.042M - Beta (5Y Monthly) 0.15
- PE Ratio (TTM)
-- - EPS (TTM)
-3.50 - Earnings Date May 10, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.71
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia.
landosbiopharma.comRecent News: LABP
Performance Overview: LABP
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LABP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LABP
Valuation Measures
Market Cap
70.15M
Enterprise Value
-3.62M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.21
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.16
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-34.11%
Return on Equity (ttm)
-61.86%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-21.93M
Diluted EPS (ttm)
-3.50
Balance Sheet and Cash Flow
Total Cash (mrq)
37.5M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-12.8M